Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic : 2C-B or Codeine or Oxybutynin

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
None (1) · (multiple, generic dominant) (1) · Ditropan, Ditropan XL, Oxytrol (transdermal), Gelnique (gel) (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1)
classes:
2C-x series (1) · Analgesic (2) · Opioid (2) · Phenethylamine (1) · Prodrug (1) · Psychedelic (1) · [[:Category:Antimuscarinics|Antimuscarinic]] (1) · [[:Category:Overactive_bladder_medications|Overactive bladder medication]] (1)
mechanism:
None (1) · 5-HT2A partial agonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)
uses:
None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000006DE-QINU`"', '"`UNIQ--vote-000006DF-QINU`"', '"`UNIQ--vote-000006E0-QINU`"' (1)
starting dose:
None (2) · Adult: 15–60 mg every 4 hours as needed. (1) · IR 5 mg PO BID-TID; ER 5-10 mg PO daily, titrate; transdermal patch 3.9 mg/d twice weekly (OTC) (1)
preparations:
None (2) · 5 mg IR tablets; 5, 10, 15 mg ER tablets; 5 mg/5 mL syrup; 3.9 mg/24 h transdermal patch (Oxytrol); 10% topical gel (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
None (2) · 30 mg/d (XL) typical (1) · 360 mg/day (1)
routes:
None (1) · insufflated (1) · intravesical (1) · Oral (2) · PO (only formulation marketed in the US). (1) · PR (1) · topical gel (1) · transdermal (1)
onset:
None (1) · 30-60 minutes (PO) (1) · 30–60 min (PO) (1) · 45-75 min (oral) (1)
duration:
None (1) · 4-8 h (1) · 4–6 hours (1) · IR: 6-10 hours; ER: 24 hours (1)
halflife:
None (1) · 2-3 hours (parent and active N-desethyl metabolite)'"`UNIQ--ref-000006E1-QINU`"' (1) · 2.5–3 hours (1) · Not well characterized (1)
bioavailability:
None (1) · Not well characterized (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~6% IR oral (substantial first-pass to active N-desethyl metabolite, which contributes most of the antimuscarinic adverse effects); transdermal bypasses first-pass and is better tolerated'"`UNIQ--ref-000006E2-QINU`"' (1)
pregnancy:
None (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)
legal:
None (1) · OTC (transdermal patch in women) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)

Showing below up to 4 results in range #1 to #4.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"